Literature DB >> 24500808

Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.

Nicholas P Forcello1, Sapna Khubchandani2, Shrina J Patel3, Driola Brahaj2.   

Abstract

Oxaliplatin is a third-generation platinum antineoplastic agent that commonly causes diarrhea, nausea, vomiting, myelosuppression, and peripheral neuropathy. Less common adverse effects that are increasingly being reported include acute immune-mediated thrombocytopenia, hemolytic anemia, and pancytopenia. Here, we report a patient case of suspected oxaliplatin-induced immune-mediated thrombocytopenia and a thorough literature evaluation of acute oxaliplatin-induced immune-mediated thrombocytopenia, hemolytic anemia, and pancytopenia that has yet to be reported until now. There have been 39 previously published reports of these cytopenic events with a median number of 16 treatment cycles prior to presentation. Patients experiencing unusual signs and symptoms such as chills, rigors, fever, back pain, abdominal pain, ecchymosis, hematemesis, hematuria, dark urine, hematochezia, petechiae, epistaxis, or mental status changes during or shortly after an oxaliplatin infusion should have complete blood counts ordered and evaluated promptly.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Oxaliplatin; hemolytic anemia; hypersensitivity reactions; immune-mediated; thrombocytopenia

Mesh:

Substances:

Year:  2014        PMID: 24500808     DOI: 10.1177/1078155213520262

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  5 in total

Review 1.  Drug-associated thrombocytopenia.

Authors:  Tamam Bakchoul; Irene Marini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.

Authors:  Brian R Curtis; Yen-Michael S Hsu; Nikolai Podoltsev; Jill Lacy; Susanna Curtis; Michael S Samuel; Kristin Zutavern; Robert A DeSimone; Daniel W Bougie; Richard H Aster
Journal:  Blood       Date:  2018-02-12       Impact factor: 22.113

3.  Humoral Immune Response of SARS-CoV-2-Infected Patients with Cancer: Influencing Factors and Mechanisms.

Authors:  Miguel Esperança-Martins; Lisa Gonçalves; Inês Soares-Pinho; Andreia Gomes; Marta Serrano; Birte Blankenhaus; Patrícia Figueiredo-Campos; Ana Catarina-Marques; Ana Castro-Barbosa; Ana Cardoso; Pedro Antunes-Meireles; Henrique Atalaia-Barbacena; Pedro Gaspar; Patrícia Howell-Monteiro; António Pais-de-Lacerda; Catarina Mota; Marc Veldhoen
Journal:  Oncologist       Date:  2021-06-03       Impact factor: 5.837

Review 4.  Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.

Authors:  Anthony Stack; Rashmi Khanal; Crystal S Denlinger
Journal:  Clin Colorectal Cancer       Date:  2020-07-30       Impact factor: 4.481

5.  Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin.

Authors:  Li-Qun Ren; Qi Li; Yang Zhang
Journal:  Biomed Res Int       Date:  2020-02-21       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.